Adult Immunization

Your daily dose of the clinical news you may have missed.

The comparable immune responses were observed in 50-to 59-year-olds at high risk of RSV-LRTD as well as a wider group at average risk, according to preliminary phase 3 data.

The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.

IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.

Reasons for not getting a COVID-19 booster ranged from worry about taking time off to believing it won't add any additional protection from infection.

AAFP president-elect Steven Furr, MD, offers 3 thoughts on maximizing opportunities this year to give all necessary vaccines.

Furr on COVID-19 shot: The expectation that 90% of the US population would take this new vaccine that they'd never heard of was probably not practical.

The combination was found equally as effective as 2 standard influenza vaccine comparators and as the Moderna Spikevax COVID-19 booster shot.

The pair of scientists was cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

Moderna reported at its annual R&D day that its flu vaccine has met primary phase 3 endpoints and that phase 1/2 data show higher HIA titers vs Fluzone HD.

"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."

SARS-CoV-2, influenza, and respiratory syncytial virus are all targets this flu season for family physician Chuck Vega, MD, who says he's "going for all 3."

RSV is comparable to influenza every year in the severity of infection among older adults. Drs Bill Schaffner and Chuck Vega say both patients and clinicians will need education this season.

As flu season approaches this year, experts stress that it's not just about influenza anymore; they discuss testing, antiviral treatment, and management of coinfection.

Well-known ID specialist Bill Schaffner, MD, and active primary care educator Chuck Vega, MD, offer thoughts on how to get shots into arms in the 2023-2024 respiratory virus season.

Respiratory virus season 2023-2024 will likely be a "transition year," according to family physician Chuck Vega, MD and ID specialist Bill Schaffner, MD. Here's why.

Eris, or EG5, is of Omicron lineage and accounts for ~17% of reported COVID-19 cases; mRNA vaccine producers are confident in the new shots to protect against it.

Findings from a new study show the long-term benefits of COVID-19 vaccination to reduce inflammation after a breakthrough infection, say researchers.

CDC immunization recommendations for influenza, COVID-19, and RSV from the updated 2023 schedules are summarized in this Guideline Topline.

A daily dose of clinical news on Patient Care you may have missed.

Which influenza vaccines does CDC recommend for older adults and how do the recommended shots differ from the others available? A short quiz.

You have tens of thousands of dollars worth of vaccines in your office fridge; your area loses power for 5 days after flooding rain. Now what?

The only head-to-head trial of mRNA COVID-19 vaccine safety in older adults finds one has a slight edge over the other, which might just be enough for some patients.

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?

Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.

The arrival of COVID-19 vaccines challenged many people for the first time to understand the actual public health role of vaccination. With the RSV shots, it may be round 2.

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

ACIP guidance on influenza vaccination for the 2023-2024 respiratory virus season includes updates important for primary care clinicians.

The real-world analysis measured the benefit of primary vaccination and of a booster and found the latter dependent upon local disease incidence and risk for severe disease.

For the 25-30 million uninsured adults in the US, the program, which will end in December 2024, will ensure access to protection from the virus for another year.